Cell Therapeutics to Resume Trading
Cell Therapeutics, the Seattle-based biotech company, said today that Italian securities regulators will allow trading in its shares to resume in Italy on Feb. 18 after it issued a statement detailing its finances. This means the company expects (NASDAQ: CTIC) to re-start trading in the U.S. on Feb. 18 as well. The company has run dangerously low on cash, with only enough money to run through February, as we described last week. Cell Therapeutics’ last traded in the U.S. at 8 cents.